The most read stories from across Cardiovascular News in July 2022 include reflections on the future of transcatheter aortic valve implantation (TAVI) from one of the pioneers of the procedure, details of an investigational device that is designed to facilitate coronary access after TAVI, and, a stark warning over the radiation exposure of echocardiographers in the cath lab.
- TAVI will continue to grow, says pioneer of the procedure
Transcatheter aortic valve implantation (TAVI) will continue to spread across the globe as more developing countries begin to adopt the procedure, Alain Cribier (Rouen, France)—who performed the world’s first TAVI procedure 20 years ago—tells Cardiovascular News.
- Investigational device offers hope of a ‘shortcut’ to prevent coronary obstruction after TAVI
Preventing coronary obstruction after transcatheter aortic valve implantation (TAVI) becomes increasingly important as the procedure moves into a lower-risk patient population. According to researchers in Europe and Israel, a new device may offer a simple solution to preventing this complication in TAVI patients.
- Stress testing can guide patient selection for coronary revascularisation
Patients identified by nuclear stress testing as having severe stress-induced myocardial ischaemia are likely to benefit from early coronary revascularisation through either coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI), while those with mild or no ischaemia are not, according to a new study published in the Journal of the American College of Cardiology (JACC).
- Female representation in interventional cardiology remains low, but there is cause for hope
Suzanne Baron and Ki Park detail some of the barriers facing women in the field of interventional cardiology, and consider some of the potential solutions to better representation in the field.
- Echocardiographers face “under-recognised” radiation exposure risk in the cath lab
Echocardiographers may be at significantly greater risk of exposure to radiation than interventional cardiologists when performing structural heart procedures in the cath lab, new research published in JAMA Network Open
- Medtronic announces co-promotion agreement with CathWorks, with path toward acquisition
Medtronic today announced it has entered into a strategic partnership agreement with CathWorks, a privately held company headquartered in Kefar Sava, Israel, which aims to transform how coronary artery disease (CAD) is diagnosed and treated.
- Ultrasound renal denervation meets primary efficacy endpoint in RADIANCE II study
ReCor Medical and Otsuka Medical Devices have announced that the RADIANCE II US Food and Drug Administration (FDA) investigational device exemption (IDE) pivotal trial evaluating the Paradise ultrasound renal denervation (uRDN) system as a treatment for hypertension met its primary efficacy endpoint.
- Genetic “cure” for cardiomyopathy is selected as winner of Big Beat Challenge
A project to develop genetic therapies to effectively cure cardiomyopathy has been announced as the winner of the British Heart Foundation’s Big Beat Challenge, a £30 million innovation project targeting unmet needs in heart disease.
- TCT MedTech Innovation Forum to spotlight opportunities for innovation
The Cardiovascular Research Foundation (CRF) and Fogarty Innovation have announced the launch of the TCT MedTech Innovation Forum, a summit dedicated to advances in medtech.
- EuroPCR 2022 hears positive results for Trilogy TAVI system in AS and AR patients
Results from the first commercial implants of the Trilogy transcatheter aortic valve implantation (TAVI) system (Jenavalve) for high-surgical risk patients with severe, symptomatic aortic stenosis (AS) or aortic regurgitation (AR) were reported at EuroPCR 2022 (17–20 May, Paris, France).